ResMed Inc. (NYSE:RMD – Get Free Report) Director Jan De Witte sold 429 shares of the stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $237.00, for a total transaction of $101,673.00. Following the completion of the sale, the director owned 3,772 shares in the company, valued at $893,964. This represents a 10.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ResMed Trading Up 2.2%
Shares of RMD opened at $243.07 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.65 and a quick ratio of 1.88. ResMed Inc. has a 1-year low of $180.26 and a 1-year high of $277.67. The stock has a market cap of $34.19 billion, a price-to-earnings ratio of 20.63, a price-to-earnings-growth ratio of 1.44 and a beta of 0.77. The firm has a 50 day simple moving average of $233.20 and a 200-day simple moving average of $224.14.
ResMed (NYSE:RMD – Get Free Report) last posted its earnings results on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $0.24. The firm had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.39 billion. ResMed had a return on equity of 26.42% and a net margin of 27.79%. ResMed’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.55 EPS. Equities analysts forecast that ResMed Inc. will post 12.14 EPS for the current fiscal year.
ResMed Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Thursday, November 12th will be issued a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, November 12th. ResMed’s payout ratio is 24.04%.
Institutional Investors Weigh In On ResMed
Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in ResMed during the second quarter worth approximately $2,400,375,000. State Street Corp boosted its holdings in shares of ResMed by 0.6% in the 2nd quarter. State Street Corp now owns 6,680,735 shares of the medical equipment provider’s stock valued at $1,301,942,000 after purchasing an additional 37,567 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of ResMed in the 2nd quarter valued at $818,030,000. First Trust Advisors LP grew its stake in shares of ResMed by 18.0% during the 3rd quarter. First Trust Advisors LP now owns 2,688,777 shares of the medical equipment provider’s stock valued at $594,489,000 after buying an additional 410,081 shares during the period. Finally, Deutsche Bank AG purchased a new stake in shares of ResMed during the 2nd quarter valued at $257,692,000. 54.98% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of analysts recently commented on the company. Weiss Ratings raised ResMed from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a research note on Friday, October 30th. Rothschild & Co Redburn assumed coverage on shares of ResMed in a research note on Wednesday, August 19th. They set a “neutral” rating and a $230.00 price target on the stock. Wells Fargo & Company lifted their price target on shares of ResMed from $215.00 to $250.00 and gave the stock an “equal weight” rating in a report on Friday, October 30th. Finally, Citigroup boosted their price objective on shares of ResMed from $240.00 to $270.00 and gave the company a “neutral” rating in a research report on Friday, October 30th. Seven research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $253.69.
View Our Latest Stock Analysis on RMD
ResMed Company Profile
ResMed is a medical technology company that develops products and software for people with sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its devices include continuous positive airway pressure (CPAP) and bilevel machines, ventilators and related masks and accessories. The company also provides cloud-connected software for managing sleep and respiratory care, along with digital tools used by home medical equipment providers and post-acute care organizations.
Recommended Stories
- Five stocks we like better than ResMed
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.
